7/27/2022 | BK | Core Laboratories amends facility, reducing size, extending maturity
|
10/16/2020 | PV | New Issue: Core Labs plans $60 million two-part private placement of senior notes
|
6/23/2020 | BK | Core Lab cuts loan to $250 million, amends pricing, leverage ratio
|
6/25/2018 | BK | Core Laboratories decreases facility to $300 million, extends maturity
|
5/11/2016 | BK | Core Laboratories to pay down revolver with proceeds of common stock
|
3/16/2015 | BK | Core Laboratories amends facility, upsizes commitment to $400 million
|
8/29/2014 | BK | Core Laboratories amends, extends $350 million revolver, reduces fees
|
9/30/2011 | BK | Core Laboratories amends, extends $300 million revolver, reduces fees
|
9/30/2011 | PV | New Issue: Core Laboratories places two series of notes totaling $150 million
|
12/20/2010 | BK | Core Laboratories amends loan, pushing out maturity and lifting size
|
10/22/2010 | CV | Core Laboratories cuts exchange rate for senior notes after dividend
|
7/21/2010 | CV | Core Laboratories updates senior exchangeable notes' exchange rate
|
4/28/2010 | CV | Core Laboratories adjusts exchange rate on senior exchangeable notes
|
2/10/2010 | CV | Core Lab adjusts exchange rate on senior exchangeables due 2011
|
10/21/2009 | CV | Core Lab adjusts exchange rate on 0.25% senior exchangeables due 2011
|
7/22/2009 | CV | Core adjusts exchange rate on 0.25% notes due 2011 following dividend
|
4/22/2009 | CV | Core Laboratories adjusts exchange rate on notes following dividend
|
7/15/2008 | CV | Core's $300 million senior exchangeable notes due 2011 are now convertible
|
9/27/2007 | SP | New Issue: RBC sells $50,000 9.3% reverse convertibles linked to Core Laboratories
|
9/10/2007 | SP | RBC to price 9.3% reverse convertibles linked to Core Labs
|
11/20/2006 | CV | Core Labs $50 million greenshoe exercised, ups exchangeables to $300 million
|
11/1/2006 | CV | New Issue: Core prices $250 million five-year exchangeables at 0.25%, up 30%, reoffered at 99.75
|
11/1/2006 | CV | Market Commentary: Charter Communications, Ceradyne climb on results; Core rises on debut; Medical Properties gains in gray
|
10/31/2006 | CV | Core Labs plans $250 million five-year exchangeables, talked at 0%-0.25%, up 30%, reoffered at 99.75
|
10/31/2006 | CV | Market Commentary: Omnicare improves hedged on results; Core Labs offered higher in gray; Medical Properties plans deal
|
12/23/2005 | BK | Core Laboratories amends loan to up size, extend tenor, lower rates
|